![]() |
市场调查报告书
商品编码
1716421
2032 年笔式针头市场预测:按类型、针头长度、分销管道、应用、最终用户和地区进行的全球分析Pen Needles Market Forecasts to 2032 - Global Analysis By Type (Standard Pen Needles, Safety Pen Needles, Short Pen Needles, Long Pen Needles, and Other Types), Needle Length, Distribution Channel, Application, End Users and By Geography |
根据 Stratistics MRC 的数据,全球注射笔针头市场预计在 2025 年达到 24.8 亿美元,预计到 2032 年将达到 45.4 亿美元,预测期内的复合年增长率为 9.0%。
笔针是一种小型、空心、中空的针,设计用于与胰岛素笔或其他注射器一起使用,以精确和可控的方式输送胰岛素或其他药物。它们具有多种长度和规格,以满足不同患者的需求,确保舒适有效的注射。糖尿病患者通常使用注射笔透过皮下注射胰岛素来控制病情。它也用于实施其他注射疗法,提供便利性并减少对注射器的需求。
根据Ipsomed在2023年11月发布的数据,该公司注射笔Uno Pen和Ipsopen的需求在过去几年中显着增长,其中Uno(现为MTD Medical Technology and Devices SpA的一部分)注射笔的销量超过1亿支,Ipsopen的销量超过1000万支。
家庭医疗保健的普及率提高
老年人口的不断增长和糖尿病盛行率的上升推动了使用注射笔针头自行注射胰岛素的需求。针头设计的进步,包括更细、更短的针头,提高了患者的舒适度和对胰岛素治疗的依从性。此外,从传统注射器到胰岛素笔的转变提高了剂量的准确性和易用性,进一步推动了市场的成长。政府推动居家医疗和扩大远端医疗服务的措施也支持了这一趋势。
缺乏培训和意识
操作或给药技术不当可能导致针刺伤、感染疾病、血糖控制不佳。在开发中地区,糖尿病教育计画的有限性加剧了这个问题,导致患者对胰岛素治疗的依从性较差。此外,对使用注射笔引起的疼痛和不适的误解可能会使一些患者不愿意使用注射笔。低收入地区的医疗保健系统通常缺乏有关胰岛素输送装置的结构化培训计划。解决这些教育差距对于充分发挥注射笔在糖尿病管理中的潜力至关重要。
提高糖尿病管理意识
国际糖尿病联盟 (IDF) 等组织发起的公共卫生宣传活动和倡议正在提高人们对现代胰岛素给药方法的认识。安全设计的针笔等技术进步因其能够减少针刺伤害并提高患者安全性而获得支持。智慧胰岛素笔等数位健康工具的集成,透过追踪剂量和提供提醒,进一步增强了糖尿病管理。糖尿病盛行率不断上升的新兴市场为市场扩张提供了尚未开发的潜力。
针刺伤风险
不当处置和处理用过的针头可能会导致意外针刺,增加传播爱滋病毒和肝炎等感染疾病的风险。监管机构已加强了针头安全的指导方针,但各地区的遵守情况有所不同。此外,安全设计的笔针价格昂贵,限制了其在资源匮乏的环境中的应用。进一步加剧问题的是,患者由于认为安全机制很复杂而不愿意使用安全机制。应对这些挑战需要不断创新针头设计并加强安全通讯协定的执行。
COVID-19 疫情以多种方式影响了针笔市场,供应链中断和医院就诊人数减少最初减缓了成长。然而,封锁期间对家庭糖尿病管理的重视程度增加,导致对胰岛素笔和笔针的需求增加。患者倾向于自我给药以避免频繁去医院,从而降低接触风险。疫情过后,对慢性病管理和预防性医疗保健的重视将继续推动市场扩张。製造商现在优先考虑有弹性的供应链和数位健康集成,以满足不断变化的患者需求。
预计安全笔针头市场在预测期内将占据最大份额
由于严格的监管准则提倡预防医疗环境中的针刺伤,因此预计安全针头部分将在预测期内占据最大的市场占有率。可伸缩针头、自动屏蔽机制和被动安全设计等创新为用户,尤其是医护人员和家庭看护者提供了更大的保护。人们对无痛超细针头的偏好日益增长,进一步推动了糖尿病患者的采用。此外,已开发地区针对安全设计设备的报销政策不断增加,有助于推动市场发展。
预计在预测期内,医院部门的复合年增长率最高。
由于糖尿病住院人数增加以及临床环境中胰岛素笔的使用增加,医院部门预计将在预测期内实现最高增长。电子健康记录(EHR) 和智慧胰岛素笔的整合增强了药物依从性和监测。此外,政府推动医院糖尿病护理标准化的倡议以及基于价值的医疗保健日益增长的趋势也促进了该领域的成长。
预计亚太地区将在预测期内占据最大的市场占有率。这是在印度和中国等国家糖尿病盛行率高且不断上升的背景下发生的。医疗保健支出的增加、政府主导的糖尿病意识计划以及胰岛素输送设备获取途径的改善正在支持市场的成长。该地区远端医疗和家庭医疗保健服务的扩展进一步推动了对注射笔针头的需求。此外,本地製造商正在推出具有成本效益的产品,使更多患者能够使用。
预计北美地区在预测期内将呈现最高的复合年增长率。这是由于先进的医疗保健基础设施、安全笔针的广泛采用以及对针刺伤害预防的强有力的监管支持。由于糖尿病管理设备的医疗保险覆盖范围广泛且患者意识不断增强,美国在该地区市场占据主导地位。联网胰岛素笔和人工智慧剂量追踪等技术进步正日益普及。此外,对糖尿病研究和数位健康解决方案的投资不断增加也促进了市场的发展。
According to Stratistics MRC, the Global Pen Needles Market is accounted for $2.48 billion in 2025 and is expected to reach $4.54 billion by 2032 growing at a CAGR of 9.0% during the forecast period. Pen needles are small, hollow, and thin needles designed for use with insulin pens or other injectable devices to administer medications, such as insulin, in a precise and controlled manner. They come in various lengths and gauges to suit different patient needs, ensuring comfortable and effective injections. Pen needles are commonly used by individuals with diabetes to manage their condition by delivering insulin subcutaneously. They are also used in the administration of other injectable treatments, offering convenience and reducing the need for syringes.
According to data published by Ypsomed in November 2023, the demand for its pen injections, UnoPen and YpsoPen, increased significantly in the past years, and sales exceeded 100 million units of Uno (now part of MTD Medical Technology and Devices S.p.A.) Pen and 10 million units of YpsoPen.
Rising adoption of home healthcare
The growing elderly population, coupled with the rising prevalence of diabetes, has amplified the demand for self-administration of insulin using pen needles. Advancements in needle design, such as thinner and shorter needles, have improved patient comfort and adherence to insulin therapy. Additionally, the shift from conventional syringes to insulin pens has enhanced dosing accuracy and ease of use, further supporting market growth. Government initiatives promoting home-based care and the expansion of telehealth services have also contributed to this trend.
Lack of training and awareness
Improper handling and administration techniques can lead to needlestick injuries, infections, and suboptimal glycemic control. In developing regions, limited access to diabetes education programs exacerbates this issue, leading to poor adherence to insulin therapy. Additionally, misconceptions about pain and discomfort associated with pen needles discourage some patients from adopting them. Healthcare systems in low-income areas often lack structured training programs for insulin delivery devices. Addressing these educational gaps is crucial to maximizing the potential of pen needles in diabetes management.
Growing awareness of diabetes management
Public health campaigns and initiatives by organizations like the International Diabetes Federation (IDF) are raising awareness about modern insulin administration methods. Technological advancements, such as safety-engineered pen needles, are gaining traction due to their ability to reduce needlestick injuries and improve patient safety. The integration of digital health tools, including smart insulin pens, further enhances diabetes management by tracking doses and providing reminders. Emerging markets with rising diabetes prevalence offer untapped potential for market expansion.
Risk of needlestick injuries
Improper disposal and handling of used needles can lead to accidental punctures, increasing the risk of bloodborne infections such as HIV and hepatitis. Regulatory bodies are enforcing stricter guidelines on needle safety, but compliance varies across regions. The high cost of safety-engineered pen needles also limits their adoption in low-resource settings. Additionally, patient reluctance to use safety mechanisms due to perceived complexity further exacerbates the issue. Addressing these challenges requires continuous innovation in needle design and stronger enforcement of safety protocols.
The COVID-19 pandemic had a mixed impact on the pen needles market, with disruptions in supply chains and reduced hospital visits initially slowing growth. However, the increased focus on home-based diabetes management during lockdowns boosted demand for insulin pens and pen needles. Patients preferred self-administration to avoid frequent hospital visits, reducing exposure risks. Post-pandemic, the emphasis on chronic disease management and preventive healthcare continues to drive market expansion. Manufacturers are now prioritizing resilient supply chains and digital health integration to meet evolving patient needs.
The safety pen needles segment is expected to be the largest during the forecast period
The safety pen needles segment is expected to account for the largest market share during the forecast period, driven by stringent regulatory guidelines promoting needlestick injury prevention in healthcare settings. Innovations such as retractable needles, automatic shielding mechanisms, and passive safety designs enhance user protection, particularly for healthcare workers and home caregivers. The growing preference for painless and ultra-thin needles further boosts adoption among diabetes patients. Additionally, increasing reimbursement policies for safety-engineered devices in developed regions support market expansion.
The hospitals segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hospitals segment is predicted to witness the highest growth rate attributed to the rising number of diabetes-related hospital admissions and the increasing use of insulin pens in clinical settings. The integration of electronic health records (EHRs) with smart insulin pens enhances medication adherence and monitoring. Furthermore, government initiatives to standardize diabetes care in hospitals and the growing trend of value-based healthcare contribute to segment growth.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by the high and growing prevalence of diabetes in countries like India and China. Increasing healthcare expenditure, government-led diabetes awareness programs, and improving access to insulin delivery devices support market growth. The expansion of telemedicine and home healthcare services in the region further boosts demand for pen needles. Additionally, local manufacturers are introducing cost-effective products, making them accessible to a larger patient population.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure, high adoption of safety pen needles, and strong regulatory support for needlestick injury prevention. The U.S. dominates the regional market due to widespread health insurance coverage for diabetes management devices and increasing patient awareness. Technological advancements, such as connected insulin pens and AI-driven dose tracking, are gaining traction. Additionally, rising investments in diabetes research and digital health solutions contribute to market acceleration.
Key players in the market
Some of the key players in Pen Needles Market include Novo Nordisk, Shanghai United Injection Device Co., Ltd., Becton, Dickinson and Company (BD), Ypsomed AG, Terumo Corporation, Mylan N.V., Medtronic, Owen Mumford, Sun Pharma, Diabetes Care, Roche Holding AG, Eli Lilly and Company, Smiths Medical, Injecto Pharmaceuticals, and Antares Pharma.
In March 2025, Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) announced that Novo Nordisk and TUL's wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd., have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.
In February 2025, Terumo Vietnam Medical Equipment (Terumo Vietnam) and Daiichi Sankyo Vietnam have signed a Memorandum of Understanding (MoU) to collaborate on advancing cardiovascular expertise in Vietnam. The initiative aims to support healthcare professionals in updating their knowledge and skills in interventional cardiology.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.